Drug Information

Drug General Information
Drug ID
D0H2JD
Former ID
DNCL002324
Drug Name
Gemcitabine prodrug
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 1 [523989], [531557]
Company
Eli Lilly
Target and Pathway
Target(s) Ribonucleoside-diphosphatereductase subunit M2 Target Info Inhibitor [528281]
Human DNA Target Info Inhibitor [528281]
BioCyc Pathway Pyrimidine deoxyribonucleotides biosynthesis from CTP
Pyrimidine deoxyribonucleotides de novo biosynthesis
Guanosine nucleotides de novo biosynthesis
Superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis
Superpathway of purine nucleotide salvage
Purine nucleotides de novo biosynthesis
Adenosine deoxyribonucleotides de novo biosynthesis
Guanosine deoxyribonucleotides de novo biosynthesis
KEGG Pathway Purine metabolism
Pyrimidine metabolism
Glutathione metabolism
Metabolic pathways
p53 signaling pathway
NetPath Pathway EGFR1 Signaling Pathway
PANTHER Pathway p53 pathway
De novo purine biosynthesis
De novo pyrimidine deoxyribonucleotide biosynthesis
Pathway Interaction Database E2F transcription factor network
PathWhiz Pathway Purine Metabolism
Pyrimidine Metabolism
Reactome E2F mediated regulation of DNA replication
G1/S-Specific Transcription
WikiPathways Nucleotide Metabolism
Retinoblastoma (RB) in Cancer
Metabolism of nucleotides
Fluoropyrimidine Activity
References
Ref 523989ClinicalTrials.gov (NCT01648764) A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread. U.S. National Institutes of Health.
Ref 531557Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clin Cancer Res. 2011 Sep 15;17(18):6071-82.
Ref 528281Cellular pharmacology of gemcitabine. Ann Oncol. 2006 May;17 Suppl 5:v7-12.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.